On Tuesday, US biotech company Novavax, which is advancing protein-based vaccines with its Matrix-M adjuvant, announced a timely update with its Nuvaxovid XBB.1 1 November 2023
The past year has been one of ups and downs for Blueprint Medicines Corporation, a US precision medicines company developing therapies for people with cancer an 20 September 2023
US biotech Cytokinetics is seeking to develop medicines that treat cardiovascular and neuromuscular diseases of impaired muscle function. 15 August 2023
Gilead Sciences subsidiary Kite prides itself on being a leader in the development of cell therapies, a claim backed by its pioneering work with Yescarta (axica 5 June 2023
As the crowds descend on Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO), The Pharma Letter interviews Eisai chief medical of 1 June 2023
The progress quietly made by Sino-American biotech company Beigene (Nasdaq: BGNE) with its oral Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) 30 March 2023
After an illustrious career as chief scientific officer at Johnson & Johnson, Dr Paul Stoffels is ready for a new chapter in his home country, with Belgian biot 2 February 2023
For years, commentators have observed that drug prices in the USA are significantly higher than elsewhere in the world. As the US Congress debates government ac 22 July 2022
One UK-based company is looking to transform the way metabolic disorders are treated, leveraging many of the same AI-based techniques used to great effect elsew 4 July 2022
The race to meet sudden, stratospheric demand for new anti-obesity meds is hotting up, but Novo Nordisk CEO Lars Fruergaard Jørgensen takes a collegiate approac 26 May 2022
In the USA and in Europe, interest in the potential for artificial intelligence to transform different aspects of the life sciences industry is at an all time h 12 May 2022
In recent years there has been an explosion of digital tools in the life sciences.but as with everything in pharma and biotech.their value hinges on the strengt 5 April 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.